Gapping down
In reaction to disappointing earnings/guidance:
- SSI -42.1%, ABMD -10.1%, TLYS -5.8%, EXAS -5.4%, EXEL -4.5%, BOOT -2%, AXDX -1.9%, ANF -1.3%, DENN -1%
Select metals/mining stocks trading lower:
- RRC -3.7%, HMY -2.4%, DRD -1.8%, GFI -1.8%, AU -1.7%, DNR -1.6%, SBGL -0.8%, AG -0.6%
Other news:
- ACST -65.6% (reports topline results for TRILOGY 1 Phase 3 Trial of CaPre; study did not reach statistical significance due to unusually large placebo effect)
- AQST -9.2% (receives FDA response to citizen's petition)
- CSOD -5% (Praesidium Investment lowers active stake below the 5% threshold following the sale of 75K shares on 1/9)
- ICAD -1% (files for $40 mln mixed securities shelf offering)
Analyst comments:
- AAP -2.9% (downgraded to Neutral from Overweight at JP Morgan and removed from Focus List)
- GVA -2.8% (downgraded to Sell from Neutral at Goldman)
- CHKP -2.1% (downgraded to Underweight from Equal-Weight at Morgan Stanley)
- EGHT -1.8% (downgraded to Equal-Weight from Overweight at Morgan Stanley)
- DOCU -1.4% (downgraded to Equal-Weight from Overweight at Morgan Stanley)
- ADSK -1.3% (downgraded to Mkt Perform from Outperform at Bernstein)
- AVT -1.3% (downgraded to Underweight from Equal Weight at Wells Fargo)